The Dutch Working Group on Melanoma also considers MM screening in patients with first- and second-degree relatives with melanoma-pancreatic carcinoma syndrome or CDKN2A mutation, 1–2 times per year, starting at 12 and 20 years old, respectively [19]. Here, CDKN2A is linked to melanoma.